Holds one active US DMF for saxagliptin, filing since 2013. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one valid CEP for saxagliptin, filing since 2026. Its 2020 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.
Holds 2 active US DMFs for saxagliptin, filing since 2013. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for saxagliptin, filing since 2019. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for saxagliptin, filing since 2013. Its 2025 FDA inspection closed as NAI.
Holds one active US DMF for saxagliptin, filing since 2024. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for saxagliptin, filing since 2013. Its 2025 FDA inspection closed as VAI.
Holds 4 active US DMFs for saxagliptin, filing since 2013. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for saxagliptin, filing since 2013. Its 2025 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for saxagliptin. Its 2025 FDA inspection closed as VAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Saxagliptin manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free